Genitope Encouraged By Positive Progression-Free Survival “Trend” In Phase III MyVax Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Final data on the personalized cancer vaccine’s use in non-Hodgkin’s lymphoma are expected in November.
You may also be interested in...
Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says
Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.
Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says
Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.
Genitope Maintains Positive View On MyVax Despite DSMB Interim Review
Data safety monitoring board recommends Genitope continue a Phase III trial of the cancer vaccine, suggesting more data is needed.